Ordaos is creating the next generation of more effective cancer and anti-viral therapeutics 30x faster than has ever been possible with its generative AI mini-protein design engine. Ordaos designs mini proteins using the Ordaos Design Engine to reduce side effects and increase drug effectiveness. As a generative AI platform, the engine simultaneously maximizes binding, stability, and manufacturability while minimizing immunogenicity and development risks as it creates proteins one amino acid at a time to meet patients’ specific needs. The result is miniPRO, Ordaos’ novel biologic drugs that are 20X smaller than monoclonal antibodies with better power and performance. miniPRO’s small size and AI-designed characteristics lead to safer, more effective drugs from the start. Ordaos miniPRO can replace any monoclonal antibody on the $250 billion global antibody therapeutics market.